Clinical trial
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects…
NCT00095277 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00095277 |
|---|---|
| Title | Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | Darbepoetin Alfa |
| Enrollment | 220 |
| Start date | Oct 1, 2004 |
| First posted | Nov 3, 2004 |
| Last update posted | Mar 13, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: